How incretin treatments affect muscle mass and function in people with overweight or obesity

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study follows adults with overweight or obesity who are starting or stopping incretin therapy. Researchers will measure changes in fat-free mass, muscle strength, and physical function at baseline, around six months, and after twelve months or at treatment discontinuation. The goal is to understand the composition of weight loss during treatment and weight regain after stopping, as well as how physical function evolves during the course. The study is conducted at Dutch clinical sites led by Radboud University Medical Center with collaboration from ZonMW. Interventions are not assigned by the study; data are collected from patients as part of routine care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Screened and planned to start with incretin treatment or currently using incretin and planned to discontinue treatment.
* Aged 18 years or older

Exclusion Criteria:

* Inability to comprehend scheduled procedures (e.g., language barriers)
* Unable to perform the physical tests due to physical disabilities
* Patients who underwent MBS or including endoscopic interventions and gastric balloon placement.
* Prior use of incretins, or other obesity medication.

Where it's running

• NOK clinics
  Amsterdam, Netherlands Recruiting
• NOK Clinics
  Nieuwegein, Netherlands Not yet recruiting

Study contacts

• Study coordinator: Puck van den Hooff
• Email: puck.vandenhooff@radboudumc.nl
• Phone: 0031 30 698 60 90

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dose find for remimazolam plus alfentanil for gastroscopy in obese adults

  This trial tests what dose of remimazolam besylate with alfentanil best sedates obese adults during gastroscopy.

  Recruiting Qianfoshan Hospital · Jinan, Shandong · NCT07925684

• Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults

  This study compares how much weight adults lose over two years when starting GLP-1 medicines versus adults who had sleeve gastrectomy at the same center.

  Recruiting Yuzuncu Yil University · Van · NCT07901777

• Gut barrier and inflammation after fast-food overfeeding in adults

  This study tests whether 14 days of fast-food overfeeding can alter gut barrier function and trigger inflammation in adults who are generally healthy.

  Recruiting University Hospital, Gentofte, Copenhagen · Hellerup · NCT07893743

• High BMI and periodontitis in Thai adults under 60

  This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.

  Recruiting Mahidol University · Bangkok, Ratchathewi · NCT07880717

• GLP-1 weight‑loss medicine: finding who will benefit most

  This study tests whether a GLP-1 drug called semaglutide helps with weight loss by changing eating behavior, to see which people it helps the most.

  Recruiting Phase 4 Universitaire Ziekenhuizen KU Leuven · Leuven · NCT07870538

• Long-term Iron Absorption in Women with Overweight/Obesity vs Normal Weight

  This study tests long-term iron absorption and loss in women aged 40–50, comparing those who are overweight/obese with those of normal weight.

  Recruiting Mahidol University · Nakhon Pathom · NCT07855939

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.